The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL)...read more
Ambrx Biopharma, a Phase 2/3 oncology biotech developing engineered antibody-drug conjugates, raised $126 million by offering 7 million ADSs at $18, within the range of $17 to $19. Ambrx Biopharma is developing a novel class of engineered precision...read more
Ambrx Biopharma, a Phase 2/3 oncology biotech developing engineered antibody-drug conjugates, announced terms for its IPO on Monday.
The La Jolla, CA-based company plans to raise $126 million by offering 7 million ADSs at a price range of $17 to $19. At the...read more
Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise...read more
US IPO Weekly Recap: IPO market in full swing as biotechs lead a 16 IPO week
The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL)...read more
China-partnered oncology biotech Ambrx Biopharma prices IPO at $18 midpoint
Ambrx Biopharma, a Phase 2/3 oncology biotech developing engineered antibody-drug conjugates, raised $126 million by offering 7 million ADSs at $18, within the range of $17 to $19. Ambrx Biopharma is developing a novel class of engineered precision...read more
China-partnered oncology biotech Ambrx Biopharma sets terms for $126 million IPO
Ambrx Biopharma, a Phase 2/3 oncology biotech developing engineered antibody-drug conjugates, announced terms for its IPO on Monday. The La Jolla, CA-based company plans to raise $126 million by offering 7 million ADSs at a price range of $17 to $19. At the...read more
US IPO Week Ahead: Biotechs and software lead a 15 IPO week
Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise...read more